)
)
)
Lactiga™ is an award-winning, venture-backed biotechnology company developing innovative mucosal antibody therapies to advance the future of immunoscience. We are unlocking the full therapeutic value of human milk to create the world’s first platform for secretory IgA antibodies. Our groundbreaking approach has the potential to transform treatment for conditions like chronic respiratory disorders, gut inflammation, immune deficiencies, and more, positioning us at the forefront of immunotherapy innovation.
Year Founded
2020
Next catalyst (value inflection) update
IND filing and Phase I PK Study in Patients
Expected time of next catalyst update
Q2 2027
City
North Brunswick
Country
United States
Company CEO or top company official
Rikin Mehta
Development Phase of Primary Product
Pre-Clinical
Lead Product in Development
LCTG-001 immune globulin A, secretory (sIgA) (human milk)
Therapeutic Area
Immunology
Website
http://www.lactiga.com
){kind=logo}
)
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
